Over the past decade, scientists have determined that the endogenous hormone fibroblast growth factor 21 (FGF21) plays a critical role in the regulation of metabolism and signaling throughout the body, acting on multiple organ systems, including the liver. The body naturally recruits FGF21 to restore health to distressed organs and ensure balance across metabolic pathways.
Akero’s lead clinical program, AKR-001 is a novel, long-acting Fc fusion modified FGF21 agonist and potential best-in-class treatment for NASH. AKR-001 builds upon two decades of work on FGF21 biology and is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.
AKR-001 was well tolerated in early clinical studies, and showed positive effects on key biomarkers of metabolic and cardiovascular disease. Akero plans to initiate Phase 2 clinical studies of AKR-001 for the treatment of NASH and is evaluating its potential to treat other serious metabolic diseases.